文献速递神经介入DSA

经皮腔内血管成形术和/或支架置入治疗基底动脉狭窄的系统综述与荟萃分析

Percutaneous transluminal angioplasty and/or stenting for the treatment of basilar artery stenosis: a systematic review and meta-analysis.
PubMed 文献 · Neuroradiology · 2023-03-07

该系统综述与荟萃分析纳入25项回顾性队列研究共1016例症状性基底动脉狭窄患者,评估经皮腔内血管成形术和/或支架置入(PTAS)的安全性与有效性。结果显示干预成功率为100%,良好最终结局率为89%,干预相关复发性缺血性卒中发生率为8.3%( actuarial rate 5%),干预相关夹层、再狭窄和死亡 actuarial rate 分别为0%、1%和0%。作者认为择期PTAS对经药物治疗无效的严重症状性非急性基底动脉狭窄患者安全有效。

要点

  • PTAS适用于双联抗血小板治疗无效的严重(≥50-70%)症状性基底动脉狭窄。
  • 干预相关复发性缺血性卒中 actuarial rate 为5%,其中穿支卒中占5.4%、支架内占2.6%、栓塞占0.4%。
  • 病变多位于基底动脉中段(51.4%),Mori-B型占57.4%,支架多选用Wingspan或Apollo。

关键影像表现/征象

  • 基底动脉狭窄最常累及基底动脉中段(51.4%),Mori-B型占57.4%。
  • 基线基底动脉狭窄中位数为81%(范围53-99%),干预后中位数为13%(范围0-75%)。
  • 干预相关复发性缺血性卒中85例(8.3%), actuarial rate 5%(95%CI 4-7%),分为穿支卒中(5.4%)、支架内(2.6%)和栓塞性(0.4%)。

诊断标准与关键数值

  • PTAS适应证为严重(≥50-70%)、症状性、双联抗血小板治疗无效的基底动脉狭窄。
  • 干预成功 actuarial rate 为100%(95%CI 100-100%),良好最终结局 actuarial rate 为89%(95%CI 85-93%)。
  • 干预相关夹层、再狭窄和死亡的 actuarial rate 分别为0%(95%CI 0-0%)、1%(95%CI 0-1%)和0%(95%CI 0-2%)。

临床应用与阅片要点

  • 阅片时需评估基底动脉狭窄部位(中段多见)和Mori分型(B型多见),以辅助治疗决策。
  • 报告应描述狭窄程度(基线中位数81%)、有无穿支梗死及支架内再狭窄等并发症。
  • 对药物治疗无效的严重症状性基底动脉狭窄,可提示PTAS为可选治疗方式。

局限性

  • 纳入研究均为回顾性队列研究,存在选择偏倚和信息偏倚可能。
  • 缺乏随机对照试验证据,无法直接比较PTAS与单纯药物治疗的疗效。
  • 各研究间支架类型、血管成形技术和抗栓方案可能存在异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Basilar artery stenosis (BAS) carries high morbidity and mortality, with variable outcomes after endovascular treatments. We systematically reviewed the literature on percutaneous transluminal angioplasty and/or stenting (PTAS) for BAS.

METHODS: PubMed, EMBASE, Web-of-Science, Scopus, and Cochrane were searched upon the PRISMA guidelines to include prospective/retrospective cohort studies describing PTAS for BAS. Pooled rates of intervention-related complications and outcomes were analyzed with random-effect model meta-analyses.

RESULTS: We included 25 retrospective cohort studies comprising 1016 patients. All patients were symptomatic, presenting with transient ischemic attack or ischemic stroke. BAS frequently involved the middle basilar artery (51.4%), mostly classified as Mori-B (57.4%). PTAS for BAS was indicated in severe (≥ 50-70%), symptomatic BAS refractory to dual antiplatelet therapy. Patients underwent angioplasty (95.5%) and/or stenting (92.2%), preferably using Wingspan or Apollo stents. Median baseline BAS was 81% (range, 53-99%), while median post-intervention BAS was 13% (0-75%). Actuarial rates of successful intervention and "good" final outcome were 100% (95% CI: 100-100%) and 89% (95% CI: 85-93%). Intervention-related recurrent ischemic stroke occurred in 85 patients (8.3%) with actuarial rates of 5% (95% CI: 4-7%), differentiated into perforator (5.4%), in-stent (2.6%), and embolic (0.4%). Actuarial rates of intervention-related dissection, restenosis, and death were 0% (95% CI: 0-0%), 1% (95% CI: 0-1%), and 0% (95% CI: 0-2%).

CONCLUSION: Elective PTAS appears to be safe and effective in selected patients with medically refractory, severe, symptomatic, and non-acute BAS. Different stent types and angioplasty-assisted procedures should be considered based on specific clinico-radiological characteristics of the lesions. Future randomized controlled trials are required to corroborate these findings.

来源:Neuroradiology,查看原文。版权归原作者所有。

引用

  1. Palmisciano, Hoz, Algburi, et al. Percutaneous transluminal angioplasty and/or stenting for the treatment of basilar artery stenosis: a systematic review and meta-analysis. Neuroradiology. 2023. PMID: 36881121. doi:10.1007/s00234-023-03124-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。